INTRODUCTION
The Comprehensive Environmental Response, Com pensation, and Liability Act (CERCLA) [42 U.S.C. 9604 et seq.] , as amended by the Superfund Amend ments and Reauthorization Act (SARA) [Pub. L. 99 499], requires that the Agency for Toxic Substances and Disease Registry (ATSDR) develop, among other mandates, toxicological profiles for substances listed on the priority list of hazardous substances found at hazardous waste sites. ATSDR must also establish sig nificant human exposure levels for hazardous sub stances in the environment and the associated acute, subacute, and chronic health effects (42 U.S.C. 9604 (i) (3)). The ATSDR's Minimal Risk Levels (MRLs) were developed as an initial response to the mandate. MRLs provide health professionals with a concept of exposure levels at which adverse health effects are not expected in human populations living in the vicinity of hazard ous waste sites or chemical emissions. By definition, an MRL is "an estimate of the daily human exposure to a hazardous substance that is likely to be without appre ciable risk of adverse, noncancer health effects over a specified duration of exposure" (ATSDR, 1996) . ATSDR categorizes hefllth effects according to their serious ness [e.g., serious, less serious (with a minimal subcat egory), not adverse] (Pohl and Abadin, 1995) . Serious effects are defined as effects that prevent the organism from functioning normally. Less serious effects are those that prevent an organ or organ system from functioning in a normal manner but will not necessar ily lead to the inability of the whole organism to func tion normally. Minimal effects are those that reduce the capacity of an organ or organ system to absorb additional toxic stress but will not necessarily lead to the inability of the organ or organ system to function normally (Pohl and Abadin, 1995) . ATSDR uses the highest no-observed-adverse-effect level (NOAEL) or lowest less serious lowest-observed-adverse-effect level (LOAEL) in the database to derive MRLs (ATSDR, 1996a; Pohl and Abadin, 1995) . As a policy, MRLs are not based on serious health effects. Categorizing the health effects is important because each respective cat egory can be assigned a different degree of uncertainty, thus affecting the final value of the calculated MRL. From the total of 272 MRLs derived by ATSDR as of December 1997, 21 were based on developmental ef fects. The purpose of this paper is to present ATSDR's ranking of developmental effects as described in the unpublished internal Guidance for Developing Toxico logical Profiles and to present those MRLs that were. based on developmental effects.
DEVELOPMENTAL EFFECTS
This section consists mostly of the revised text on developmental effects as written in the Guidance for Developing Toxicological Profiles (ATSDR, 1995a 
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Could be considered serious, depending on the degree of severity.
Health Sciences (NIEHS). For developmental effects, specific directions were excerpted from EPA (1986, 1989) documents. Later, some parts were rewritten by ATSDR staff with special attention given to assigning health effects to appropriate categories according to their severity. As defined in the ATSDR (1995a) guidance, develop mental toxicity is any adverse effect on the developing organism from implantation through prenatal develop ment or postnatally to the time of sexual maturation. These effects can result from exposure prior to implan tation (either parent) or during prenatal and postnatal development. Systemic, immunological, or neruological effects seen in the developing organism prior to sexual maturity may be considered secondary to adverse de velopmental effects.
Developmental effects are distinguished from repro ductive effects by evaluation of the conceptus after it is implanted. Developmental effects can be categorized as structural abnormalities, altered growth, functional deficiencies, congenital neoplasia, and death of the de veloping organism. Examples of specific end points within three of these effect categories are listed and classified as serious or less serious in Table 1 .
Structural abnormalities include malformations and variations, which also may be referred to as anomalies, deformations, or aberrations. The term "teratogenic ity" is used to describe permanent structural abnor malities that may adversely affect survival, develop ment, or function.
Altered growth can be induced at any stage of devel opment, may be reversible, or may result in permanent change. Changes in the mother (dam) can influence or confound interpretation of altered growth in the fetus or neonate. In general, altered growth seen in conjunc tion with adverse effects in dams, such as decreased weight gain, has been treated as an adverse effect in the fetus or neonate.
Functional deficiency is defined as alterations or de lays in the functional competence of the organism or organ system following exposure to an agent during critical periods of development either prenatally or postnatally. Examples include:
• Immunosuppression (suppression of natural im mune responses) in offspring. Immune dysfunction may lead to increased risk of infectious diseases or to development of neoplasia, autoimmune disorders, or allergies.
• Neurobehavioral development in offspring. Many neurobehavioral tests are used in studies of newborns to assess abnormalities in developing offspring. Mea surement of the course of development of swimming behavior, for example, is a common technique for the evaluation of neuromotor development. The neuromo tor system is the system commonly studied when func tional development is being assessed. Evaluation of motor development must be of primary consideration in detecting toxicity because the performance ofcertain responses is known to be influenced by the testing conditions used and the motivational state of animals. To accurately assess the behavioral effects of any sub stance, a test battery must use multiple behavioral end points.
• Inborn errors of metabolism. Genetically based in born errors of metabolism are not usually expressed before birth. They are disorders in which defects of single genes cause clinically significant blocks in met abolic pathways. Clinical effects are mostly a result of either an accumulation of enzyme substrate or a defi ciency of the reaction product. Examples of inborn er rors of metabolism include disorders of carbohydrate metabolism (e.g., glycogen storage diseases), amino acid metabolism (e.g., phenylketonuria), fatty acid ox idation (e.g., glutaric acidemia), and purine metabo lism (e.g., hypoxanthine-guanine phosphoribosyl transferase deficiency).
• Abnormal postnatal reproductive function. Such effects can be detected in long-term multigenerational studies.
Congenital neoplasia. Fetal cells are highly suscep tible to carcinogens because of their high rate of pro liferation. Transplacental carcinogens can act either directly or through reactive metabolic intermediates. The latter carcinogens require the fetal enzyme levels to be sufficient to metabolize the original agent to its active form. Many teratologic disorders are associated with neoplasms. Examples in humans include associa tion of aniridia with Wilms' tumor, trisomy 21 with leukemia and retinoblastoma, 13q syndrome with ret inoblastoma, and Fanconi's anemia with leukemia and squamous cell carcinoma.
Death. Embryonic cells are very sensitive to expo sure to toxic chemicals. In early stages of development, when cells differentiate into more specialized cell pop ulations, cell death may result in structural malforma tions or death of the embryo. In humans, it is estimated that 50-70% of all conceptuses are aborted during the first 3 weeks of pregnancy. As with all experiments in laboratory settings, it is important to evaluate the im pact of the toxic substance on death of the embryo in comparison with the control group.
Maternal toxicity. Findings of developmental toxic ity in the presence of maternal toxicity (i.e., when adverse developmental effects are produced only at maternally toxic doses) are still considered to represent developmental toxicity and should not be discounted as being secondary to maternal toxicity. Maternal toxicity (even in the absence of developmental toxicity) is an important end point to evaluate in the context of all available toxicity data. The following are some exam ples of maternal toxicity end points.
• Mortality • Gestation length (when allowed to deliver pups) • Body weight • Body weight change • Organ weights (in cases of suspected organ toxicity and when supported by adverse histopathology find ings)
• Food and water consumption (where relevant)
• Clinical evaluations, including types and incidence of clinical signs, enzyme markers, and clinical chemis tries
• Gross necropsy and histopathology.
Body weight and changes in body weight are viewed collectively as indicators of maternal toxicity for most species. These end points may not be as useful in rabbits, because body weight changes in rabbits are not good indicators of pregnancy status. Changes in ma ternal body weight corrected for gravid uterine weight at sacrifice may indicate whether the effect is primarily maternal or fetal. For example, there may be a signif icant reduction in weight gain and in gravid uterine weight throughout gestation but no change in cor rected maternal weight gain, which would generally indicate an intrauterine effect. Conversely, a change in corrected weight gain and no change in gravid uterine weight generally suggest maternal toxicity and little or no intrauterine effect.
Because the maternal animal and not the conceptus is usually treated during gestation, developmental tox icity data may be presented as incidence per litter or as number and percentage of litters with particular end points. Some of the end points can be categorized as developmental and/or reproductive end points. Repro ductive effects are discussed in detail in the section on reproductive effects of the ATSDR (1995a) guidance.
MRLs BASED ON DEVELOPMENTAL EFFECTS
As of December 1997, ATSDR's MRL Workgroup had derived 21 MRLs based on developmental effects. These MRLs and the specific end points that served as the bases for their derivation are listed in Table 2 . Most MRLs were based on developmental effects seen in laboratory ani mals following exposures in utero or during the early days of postnatal development. Only one MRL, that for methylmercury, was based on effects seen in humans. Animal data used in inhalation studies were converted to human equivalent concentrations by using dosimetry ad justment in accordance with EPA (1990) (1988) . Uncer tainty factors (UFs) used in actual computations of respective MRLs are listed in Table 2 . The UFs account for extrapolation from a LOAEL to a NOAEL, for extrap olation from animals to humans (interspecies extrapola tion), and for human variability (sensitive populations). ATSDR's practice in utilization ofUFs in MRL derivation was described in detail in our previous publication (Pohl and Abadin, 1995) .
MRLs for acrylonitrile, di(2-ethylhexyl)phthalate, and ethylbenzene were based on NOAELs for terato genic end points. At higher doses, skeletal and/or vis ceral malformations were detected in exposed animals (e.g., exencephaly, blood vessel abnormalities, fused or branched ribs, fused thoracic vertebrae). If NOAELs had not been established in these studies, the LOAELs would not have been suitable for MRL derivation be cause of the seriousness of these effects (Table 1) . As discussed previously, most teratogenic effects ad versely alter survival, development, or function of the affected individual and are, therefore, not suitable for MRL derivation.
Several MRLs were based on LOAELs for neurobe havioral end points that were categorized as less seri ous. Delayed cognitive function was the end point used in the MRL derivation for chlordane, whereas delayed motor function was used for DDT, xylenes, and trichlo roethylene. Increased seizure threshold was the lowest LOAEL suitable for MRL derivation in the database of aldrin and chlordane, and hyperactivity was used for the MRL derivation for hexachlorobenzene and tetra chloroethylene. Mild behavioral changes that included alterations in play behavior, displacement, and self directed behavior in the offspring of monkeys exposed chronically to 2,3,7,8-tetrachlorodibenzo-p-dioxin were used as end points for the MRL derivation for this chemical.
Neurotoxicity is also an important end point for the evaluation of toxic substances. Progression and irre versibility of many neurologic effects add to the long term implications. Infants and developing fetuses might be more susceptible to neurobehavioral effects (Who, 1986) . In addition, effects of exposure may not be apparent until later in life, when functional losses re sulting from chemical exposures may be debilitating. Note. d, day; draft, draft for public comments of the toxicological profile for respective chemicals; F 0, parental generation; F 1> the first generation produced by crossing two parental lines; final, final draft of the toxicological profile for respective chemicals; Gd, gestation day; Ld, lactation day; LOAEL, lowest-observed-adverse-effect level; MRL, minimal risk level; NOAEL, no-observed-adverse-effect level; Ppd, postpartum day; UF, uncertainty factor, wks, weeks.
a Final toxicological profile peer-reviewed and public reviewed published on date indicated. b Draft toxicological profile peer-reviewed and released for public comments on date indicated.
In general, neurotoxic effects are due to structural or functional alterations in central and peripheral ner vous systems. The underlying defects may include damage of neurons and axons; myelinopathies; effects on neurotransmitters, end plates, and synapses; effects on central nervous system (CNS) metabolism; or circu latory changes (Koestner and Norton, 1991) . Batteries of neurobehavioral tests have been developed for eval uating neurotoxicity in humans and laboratory ani mals (ATSDR, 1995b (ATSDR, , 1996b . Some of the changes reported in experimental studies are very subtle; oth ers may be apparent in one test but not in a different test designed to evaluate the same end point. There fore, classification of NOAELs and less serious or seri ous LOAELs becomes critical for the development of health guidance values. Because neurobehavioral toxicity is a recently devel oped discipline, not enough data are yet available to develop animal models that parallel or convincingly simulate known effects in humans. Evidence of simi larities may often be concealed by inadequate testing or interpretation of data, interspecies differences in developmental maturity of the CNS, and differences in behavioral patterns. UFs for interspecies extrapolation used in health risk assessment acknowledge these dif ferences and the reservations associated with them. It is, however, recognized that mild, subclinical behav ioral or neurologic changes can be early indicators of an important ongoing disease process (ATSDR, 1995b). As such, these effects must be considered in the thorough health assessment of developing organisms.
Impaired fetal growth and early neonatal growth are nonspecific markers of intrauterine insult. They may be associated with maternal toxicity. The outcome of the chemical insult during gestation may be embryolethality, teratogenicity, or growth retardation depending on the chemical, the period of fetal development, and the dose. There are three patterns of dose-response relationship between growth retardation, teratogenicity, and embryo lethality (Manson and Wise, 1991) . For some chemicals, malformed fetuses often have decreased growth and the effects precede lethality (i.e., teratogenicity is a main manifestation ofthe primary insult). In other instances, a combination of embryolethality, teratogenic effects, and growth retardation can be seen at the same dose levels (i.e., these are all manifestations of the primary insult). Chemicals may also cause lethality at a higher dose and growth retardation at a lower dose without inducing mal formations (i.e., embryolethality is a main manifestation of the primary insult). Embryolethality and teratogenic ity are mostly considered as serious effects (Table 1) and are not suitable for MRL derivation (ATSDR, 1995a) . Unless the weight decreases are so profound that they could interfere with further proper development and/or survival, they are categorized as less serious. A LOAEL for reduced fetal weight was the basis for the intermedi ate-duration oral MRL for boron. At higher exposure levels, teratogenic effects (rib cage defects) and embryolethality (high resorptions) were reported (Heidel et al., 1991) . For di-N-butylphthalate, the MRL was based on a NOAEL for decreased weight of offspring of exposed rats.
Skeletal development is another important end point in developmental toxicology studies. Delayed ossifica tion can be associated with decreased fetal weight, but can also occur sporadically. Subtle structural changes due to delayed ossification are often considered revers ible (Aliverti et al., 1979) and can, therefore, be classi fied as less serious for the purpose of MRL derivation. Delayed ossification was the end point for MRL deri vation in the case of pentachlorophenol exposure. Skel etal anomalies were reported with higher exposure levels, suggesting a progression of severity of skeletal effects with increasing dose.
As described previously, developmental effects can be categorized according to the degree of severity. Be cause many developmental effects belong to the serious category (Table 1) , and ATSDR does not base MRLs on serious effects (ATSDR, 1996a), serious developmental effects observed at the lowest effect levels in the data base precluded the derivation of MRLs for several chemicals. For example, an intermediate-duration oral MRL for trichloroethylene was not derived because the most sensitive end point in the database was a devel opment of serious cardiac anomalies in the offspring of exposed rats (Dawson et al., 1993) . CONCLUSION ATSDR acknowledges that a considerable amount of judgment may be required in establishing whether an end point should be classified as a NOAEL, minimal LOAEL, less serious LOAEL, or serious LOAEL. The distinctions between these categories are important because they help health assessors identify levels of exposure at which major health effects start to appear and place into perspective the possible significance of these effects to human health.
Developmental effects are important because not only is the parental generation affected by the chemical exposure, but there are also consequences to future generations. It is important for ATSDR to properly categorize developmental effects and to recognize pos sible impacts on human populations.
